Sciencebiotech
Modified CAR T cells with added receptor target bone marrow tumors
Recent scientific research explores how modifying CAR T cells by adding a specific receptor can help them persist within the bone marrow in cancer mouse models. This advancement addresses a major limitation in treating solid tumors and bone-localized cancers using engineered immune cells. While CAR T-cell therapy has achieved remarkable success against blood cancers, solid tumors present severe barriers due to the suppressive microenvironment and poor cell homing. Enhancing bone marrow retention marks a notable step forward in overcoming these obstacles.